CAR T cell therapy for IL13Rα2 positive pediatric brain tumors
Treatments studied
Part of Brain & nervous system, Cancer clinical trials.
This Phase 1 study tests a type of immune therapy (CAR T cells) for children with brain tumors that come back or do not respond to standard treatment. The cells are given after chemotherapy that temporarily lowers the body’s immune system, which may help the CAR T cells work better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child must have a confirmed malignant brain tumor that has progressed after prior standard treatment, and it must be measurable on scans after at least 12 weeks.
- Tumor tissue must show IL13Rα2 positivity (the study lab confirms the marker on biopsy tissue).
- Child must be able to carry out daily activities fairly well (Karnofsky 60% or higher, with flexibility if limited mainly by disease-related mobility issues).
- Recent blood tests must be safe enough: platelets at least 50,000, liver tests (bilirubin/ALT/AST) under set limits, and kidney function adequate (creatinine clearance ≥ 75).
- No serious breathing, heart, kidney failure (no dialysis), or uncontrolled seizure problems right before treatment; no active infection and no oxygen needed to keep levels >95%.
- Treatment timing must fit: enough time since last chemotherapy/radiation/targeted drugs, and enough time between the immune “wash-out” periods.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new CAR T cell therapy (BCB-276) for children and young adults with a type of brain tumor called DIPG. The therapy uses your own immune cells that are specially trained to attack the cancer.
This trial tests genetically engineered immune cells (CAR T cells) injected directly into the brain to treat recurring or worsening high-grade gliomas. The cells are designed to recognize and attack tumor cells that have specific markers (EGFR and IL13Rα2).
This Phase 1 study tests an experimental CAR T-cell treatment that targets GD2, with added immune-boosting and safety features, for children with relapsed or refractory neuroblastoma or osteosarcoma. It’s designed to see if the treatment is safe and can shrink these cancers when standard therapy hasn’t worked.
This Phase 1 trial tests a personalized immune-cell treatment (CAR T) delivered directly in the brain-area space using a catheter. It may help children and young adults with hard-to-treat (recurrent or refractory) diffuse midline brain tumors like DIPG/DMG when standard options aren’t working.
This trial tests a new kind of immunotherapy for children and teens with solid tumors that have not responded to standard treatments. The therapy uses specially engineered T cells (CAR T cells) that target a protein called GPC3 found on many tumor cells, and it includes extra signals (IL-15 and IL-21) to help the T cells work better.
This trial tests a new type of immunotherapy called CAR T cells—immune cells engineered in the lab to fight a specific brain tumor called ATRT (atypical teratoid rhabdoid tumor). The cells are designed to recognize and attack tumor cells that have a protein called GPC3, and are enhanced with immune-boosting signals to work better.
Hear when a new Malignant Brain Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.